Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia.

[1]  Stefanie Hennig,et al.  A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. , 2007, British journal of clinical pharmacology.

[2]  A. Glasmacher,et al.  Safety and Efficacy of Itraconazole Compared to Amphotericin B as Empirical Antifungal Therapy for Neutropenic Fever in Patients with Haematological Malignancy* , 2007, Oncology Research and Treatment.

[3]  A. Glasmacher,et al.  Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants , 2007, Supportive Care in Cancer.

[4]  J. Donnelly,et al.  Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation , 2006, Antimicrobial Agents and Chemotherapy.

[5]  Mikiko Shimizu,et al.  Sensitive Determination of Itraconazole and Its Active Metabolite in Human Plasma by Column-switching High-performance Liquid Chromatography With Ultraviolet Detection , 2006, Therapeutic drug monitoring.

[6]  A. Gorelik,et al.  A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients , 2006, Bone Marrow Transplantation.

[7]  A. Glasmacher,et al.  An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. , 2006, The Journal of antimicrobial chemotherapy.

[8]  S. Bell,et al.  Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients , 2006, Clinical pharmacokinetics.

[9]  L. Pagano,et al.  Design and Methods , 2022 .

[10]  A. Glasmacher,et al.  Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. , 2005, The Journal of antimicrobial chemotherapy.

[11]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[12]  Stephen B. Duffull,et al.  Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  J. Golden,et al.  Intrapulmonary Pharmacokinetics and Pharmacodynamics of Itraconazole and 14-Hydroxyitraconazole at Steady State , 2004, Antimicrobial Agents and Chemotherapy.

[14]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[15]  D. Peckham,et al.  Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. , 2004, The Journal of antimicrobial chemotherapy.

[16]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[17]  J. Klastersky.  Empirical antifungal therapy. , 2004, International journal of antimicrobial agents.

[18]  B. Djulbegovic,et al.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Territo,et al.  Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.

[20]  C. R. Pinkerton,et al.  Role of itraconazole in haematology/oncology , 2003, Archives of disease in childhood.

[21]  J. Meis,et al.  Prophylaxis and treatment of fungal infections associated with haematological malignancies. , 2000, International journal of antimicrobial agents.

[22]  T. Naoe,et al.  Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. , 1999, International journal of hematology.

[23]  T. Sauerbruch,et al.  Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl‐β‐cyclodextrin oral solution or coated‐pellet capsules , 1999, Mycoses.

[24]  P. Veys,et al.  Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders , 1999, Bone Marrow Transplantation.

[25]  C. Leutner,et al.  Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia , 1998, Leukemia.

[26]  G. Cheymol,et al.  Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen. , 1997, Therapeutic drug monitoring.

[27]  W. Leisenring,et al.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.

[28]  Laboratory monitoring of antifungal chemotherapy. British Society for Antimicrobial Chemotherapy Working Party. , 1991, Lancet.

[29]  S. Clissold,et al.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.

[30]  G. Verhoef,et al.  Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels , 1989, Mycoses.

[31]  R. M. Tucker,et al.  Treatment of invasive aspergillosis with itraconazole. , 1989, The American journal of medicine.

[32]  S. Clissold,et al.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.